Research graph
References from Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling. Local targets link to admitted publications; unresolved targets remain external evidence.
ANCA-associated vasculitis
10.1038/s41572-020-0204-y · 2020 · External reference
Risk factors for serious infections in ANCA-associated vasculitis
10.1136/ard-2022-223401 · 2023 · External reference
Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis
10.1136/rmdopen-2023-003956 · 2024 · External reference
Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis
10.1007/s00296-020-04752-9 · 2021 · External reference
Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study
10.1093/mr/roaf053 · 2025 · External reference
Risk factors for serious infections and infection-related mortality in patients with microscopic polyangiitis: multicentre REVEAL cohort study
10.1093/mr/roae024 · 2024 · External reference
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
10.1681/asn.2016111179 · 2017 · External reference
Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis
10.1002/acr2.11185 · 2020 · External reference
Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis
10.1016/j.ekir.2024.03.022 · 2024 · External reference
The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis: first experiences in Spain
10.1093/rheumatology/keae534 · 2025 · External reference
Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option
10.1016/j.ekir.2022.01.1065 · 2022 · External reference
Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting
10.1016/j.ekir.2024.07.007 · 2024 · External reference
Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study
10.1093/rheumatology/keae359 · 2025 · External reference
Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis
10.1016/j.ekir.2021.11.036 · 2022 · External reference
2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides
10.1002/art.37715 · 2013 · External reference
2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for granulomatosis with polyangiitis
10.1136/annrheumdis-2021-221795 · 2022 · External reference
2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for microscopic polyangiitis
10.1136/annrheumdis-2021-221796 · 2022 · External reference
The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort
10.1097/md.0b013e318205a4c6 · 2011 · External reference
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
10.1136/ard.2006.062711 · 2007 · External reference
Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review
10.1016/j.semarthrit.2020.09.010 · 2020 · External reference
The role of anti-neutrophil cytoplasm antibody specificity in predicting relapse in ANCA-associated vasculitis
2022 · External reference
Remission induction therapies and long-term outcomes in granulomatosis with polyangiitis and microscopic polyangiitis: real-world data from a European cohort
10.1007/s00296-024-05757-4 · 2024 · External reference
C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling
10.1172/jci.insight.137029 · 2020 · External reference
C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients
10.1182/blood-2010-08-304667 · 2011 · External reference
